Tyra Biosciences Inc (TYRA) — Cash Flow-to-Debt Ratio
Latest as of December 2025:
-1.01x
Tyra Biosciences Inc (TYRA) has a Cash Flow-to-Debt Ratio of -1.01x as of December 2025, meaning its operating cash flow of $-23.62 Million could theoretically repay -1% of its total liabilities ($23.43 Million) in one year. See how financially flexible is Tyra Biosciences Inc to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
-1.01x
Operating CF / Total Liabilities
Operating Cash Flow
$-23.62 Million
USD
Total Liabilities
$23.43 Million
USD
Data as of
Dec 2025
Most recent filing
Tyra Biosciences Inc Cash Flow-to-Debt Ratio (2019–2025)
Historical debt coverage capacity for Tyra Biosciences Inc across 7 annual periods. For the full cash flow conversion analysis, see Tyra Biosciences Inc (TYRA) cash flow conversion.
Annual Cash Flow-to-Debt Ratio for Tyra Biosciences Inc (2019–2025)
Year-by-year debt coverage analysis for Tyra Biosciences Inc.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -4.06x | $-95.14 Million | $23.43 Million | ▼ -18.8% |
| 2024 | -3.42x | $-69.77 Million | $20.41 Million | ▼ -47.3% |
| 2023 | -2.32x | $-50.14 Million | $21.59 Million | ▲ +61.4% |
| 2022 | -6.02x | $-50.28 Million | $8.35 Million | ▼ -25.9% |
| 2021 | -4.78x | $-23.75 Million | $4.96 Million | ▼ -1726.9% |
| 2020 | -0.26x | $-7.76 Million | $29.65 Million | ▲ +47.3% |
| 2019 | -0.50x | $-2.62 Million | $5.27 Million | — |
Cash Flow-to-Debt Ratio = Operating Cash Flow / Total Liabilities. Higher is better for debt service capacity.